In the past decade, target therapy such as the EGFR tyrosine kinase inhibitors (TKIs) treatment has significantly improved the survival out advanced‐stage NSCLC with driver oncogene mutations; however, almost all patients develop resistance.4, 5. Here, EGFR is linked to non-small cell lung carcinoma.